VP Corporate Development - Isotope Strategy - Growing Radiopharmaceutical Company
Planet Pharma is currently working with a growing radiopharmaceutical company based out of the UK and they are looking for someone to join the business as their VP Corporate Development.
This company have developed a revolutionary nuclear fusion device for cancer therapies, completely changing the landscape for radiopharmaceuticals in the cancer space. This is a really exciting role in which you can have a hands-on impact on the business growth and success in a market dominated by big players radiopharmaceuticals and medical isotopes.
A big part of this role will be all about isotope strategy and how you position this strategy on the market amongst the radiopharmaceutical space. You will also be responsible for:
* Negotiating contracts and business deals including the sourcing or rare materials/isotopes
* Interact with key stakeholders like customers, companies and clients to understand their needs
* Negotiate partnerships with academia, IP rights and the sale of products
Your goal is help this company position themselves in the market and execute a 'be in it to win it' strategy.
For this position my client is looking for an expert in the world of radiopharmaceuticals and medical isotopes. You must have extensive experience in these fields and understand the needs of the market as well potential gaps in the market to capitalise on. You will also have:
* A commercial mindset/background to be able to sell this company and their vision to the wider market
* Experience in sourcing rare materials/isotopes including negotiating contracts for the sourcing of these materials
* An understanding of the supply chain of rare materials/isotopes
This is a fully hybrid role and can be based anywhere in the UK, Europe or the US/Canada.
For more information on this position or any similar opportunities, please contact Chanel Hicken on 0044 (0)203 868 1011 or email chanel.hicken@planet-pharma.co.uk and we can arrange a time to discuss this opportunity further.